Source:http://linkedlifedata.com/resource/pubmed/id/12868555
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2003-7-18
|
| pubmed:abstractText |
The aim of this phase II study was to investigate the tolerance and efficacy of a second-line irinotecan/mitomycin C combination in patients with advanced gastric or colorectal cancer, pretreated with 5-fluorouracil. Forty patients who had received 5-fluorouracil-based chemotherapy for advanced disease or adjuvant 5-fluorouracil treatment were enrolled. Chemotherapy consisted of irinotecan 125 mg/m2 and mitomycin C 5 mg/m2, given every 2 weeks. Treatment was continued until progression or limiting toxicity occurred. Five partial responses (12.5%), 22 cases of stable disease (55%) and 13 of progression (32.5%) were registered, giving an overall response rate of 12.5% [95% confidence interval (CI), 4.2-26.8%] and an overall control of tumor growth in 67.5% (95% CI, 50.8-81.4%) of patients. Median progression-free survival was 5 months, median survival time 8 months, and 1-year probability of survival was 21.6%. Diarrhea and neutropenia affected 25% and 12.5% of patients respectively, with only 7.5% experiencing grade 3-4 toxicity. There were no chemotherapy-related deaths or hospitalizations. This combination regimen was shown to be moderately effective with substantially lower toxicity than irinotecan monotherapy in 5-fluorouracil-pretreated patients with advanced gastric or colorectal cancer. It may represent an attractive option in patients at high risk for developing specific irinotecan toxicity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1120-009X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
15
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
275-81
|
| pubmed:dateRevised |
2009-8-4
|
| pubmed:meshHeading |
pubmed-meshheading:12868555-Adenocarcinoma,
pubmed-meshheading:12868555-Adult,
pubmed-meshheading:12868555-Aged,
pubmed-meshheading:12868555-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12868555-Camptothecin,
pubmed-meshheading:12868555-Chi-Square Distribution,
pubmed-meshheading:12868555-Colorectal Neoplasms,
pubmed-meshheading:12868555-Dose-Response Relationship, Drug,
pubmed-meshheading:12868555-Drug Administration Schedule,
pubmed-meshheading:12868555-Drug Toxicity,
pubmed-meshheading:12868555-Female,
pubmed-meshheading:12868555-Fluorouracil,
pubmed-meshheading:12868555-Follow-Up Studies,
pubmed-meshheading:12868555-Humans,
pubmed-meshheading:12868555-Male,
pubmed-meshheading:12868555-Maximum Tolerated Dose,
pubmed-meshheading:12868555-Middle Aged,
pubmed-meshheading:12868555-Mitomycin,
pubmed-meshheading:12868555-Neoplasm Staging,
pubmed-meshheading:12868555-Odds Ratio,
pubmed-meshheading:12868555-Probability,
pubmed-meshheading:12868555-Risk Assessment,
pubmed-meshheading:12868555-Salvage Therapy,
pubmed-meshheading:12868555-Stomach Neoplasms,
pubmed-meshheading:12868555-Survival Analysis
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
|
| pubmed:affiliation |
Oncology Dept, Ioannina University Hospital, Ioannina, Greece. abamias@med.uoa.gr
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Clinical Trial, Phase II
|